Maklumat tambahan indikasi
Year 2017
Products Approved For Additional Indication (DCA 314 – 3 August 2017)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 **CYCLOGEST 400MG PESSARIES** [PROGESTERONE 400MG]	➢ Indication: *Luteal phase support as part of an Assisted Reproductive Technology (ART) treatment for women. (Only for Cyclogest 400mg pessary)* ➢ Posology: *For luteal phase support as part of an ART treatment:* *400 mg administered vaginally twice a day starting at oocyte retrieval. The administration of Cyclogest should be continued for 38 days, if pregnancy has been confirmed.* *Use in special populations:* *There is no experience with use of Cyclogest in patients with impaired liver or renal function.* *Paediatric population:* *There is no relevant use of Cyclogest in the paediatric population.* *Elderly:* *No clinical data have been collected in patients over age of 65.*	**ACTAVIS SDN BHD** Lot No. 8F-1B, 8th Floor Tower 4 @ PFCC, Jalan Puteri 1/2 Bandar Puteri 47100 Puchong, Selangor